Cytogenotoxic effects of two potential anticancer Ruthenium(III) Schiff Bases complexes

  • Izet Eminovic University of Sarajevo, Faculty of Science, Department for Biology
  • Emira Kahrovic
  • Aner Mesic University of Sarajevo, Faculty of Science, Department for Biology
  • Emir Turkusic University of Sarajevo, Faculty of Science, Department for Chemistry
  • Dzenana Kargic University of Sarajevo, Faculty of Science, Department for Biology
  • Adnan Zahirovic University of Sarajevo, Faculty of Science, Department for Chemistry
  • Zana Dolicanin State University of Novi Pazar, Vuka Karadzica bb, 36300 Novi Pazar, Serbia

Abstract

Introduction: Treatment of cancer has been subject of great interest. Researchers are continuously searching for new medicines. In this sense, ruthenium complexes have big potential. Some evidences suggest that ruthenium compounds possess anticancer activities. We synthesized two recently published ruthenium(III) complexes with bidentate O,N and tridentate O,O,N Schiff bases derived from 5-substituted salicylaldehyde and aminophenol or anilineare. These compounds showed affinity for binding to the DNA molecule, however, insufficient data are available regarding their possible toxic effects on biological systems.

Methods: In the present study we evaluated genotoxic, cytotoxic, and cytostatic effects of Na[RuCl2(L1)2] and Na[Ru(L2)2], using the Allium cepa assay.

Results: Different toxic effects were observed depending on the substance, tested concentration, and endpoint measured. In general, the tested compounds significantly lowered the root growth and mitotic index values as compared to the control group. Additionally, a wide range of abnormal mitotic stages, both clastogenic and non-clastogenic were observed in the treated cells. Na[RuCl2(L1)2] significantly increased the frequency of sticky metaphases, chromosome bridges, micronuclei, impaired chromosome segregation, as well as number of apoptotic and necrotic cells over the controls. In contrast, Na[Ru(L2)2] did not show significant evidence of genotoxicity with regard to chromosome aberrations and micronuclei, however, significant differences were detected in the number of apoptotic and necrotic cells when the highest concentration was applied.

Conclusions: In this study we demonstrated antiproliferative effects of Na[RuCl2(L1)2] and Na[Ru(L2)2]. At clinical level, these results could be interesting for further studies on anticancer potential of the ruthenium(III) complexes using animal models.

Author Biography

Emira Kahrovic
University of Sarajevo, Faculty of Science, Department for Chemistry

References

1. Kostova I. Ruthenium complexes as anticancer agents. Curr Med Chem. 2006;13(9):1085-107.
http://dx.doi.org/10.2174/092986706776360941.
2. Sava G, Zorzet S, Giraldi T, Mestroni G, Zassinovich G. Antineoplastic activity and toxicity of an organometallic complex of ruthenium(II) in comparison with cis-PDD in mice bearing solid malignant neoplasms. Eur J Cancer Clin Oncol. 1984;20(6):841-47.
http://dx.doi.org/10.1016/0277-5379(84)90223-2.
3. Sava G, Bergamo A. Ruthenium-based compounds and tumour growth control (review). Int J Oncol. 2000;17(2):353-65. http://dx.doi.org/10.3892/ijo.17.2.353.
4. Sharma AR, Gangrade DM, Bakshi SD, John JS. Ruthenium complexes: Potential candidate for anti-tumour activity. Int J ChemTech Res. 2014;6(1):828-37.
5. Allardyce CS, Dyson PJ. Ruthenium in medicine: Current clinical uses and future prospects. Platin Met Rev. 2001;45(2):62-9.
6. Antonarakis ES, Emadi A. Ruthenium-based chemotherapeutics: Are they ready for prime time? Cancer Chemother Pharmacol. 2010;66(1):1-9.
http://dx.doi.org/10.1007/s00280-010-1293-1.
7. Gagliardi R, Sava G, Pacor S, Mestroni G, Alessio E. Anti-metastatic action and toxicity on healthy tissues of Na[trans-RuCl4(DMSO)Im] in the mouse. Clin Exp Metastasis. 1994;12(2):93-100. http://dx.doi.org/10.1007/BF01753975.
8. Bergamo A, Masi A, Dyson PJ, Sava G. Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound. Int J Oncol. 2008;33(6):1281-9.
9. Anitha P, Chitrapriya N, Jang YJ, Wiswanathamurthi P. Synthesis, characterization, DNA interaction, antioxidant and anticancer activity of new ruthenium(II) complexes of thiosemicarbazone/semicarbazone bearing 9,10-phenanthrenequinone. J Photochem Photobiol. 2013;129(C):17-26. http://dx.doi.org/10.1016/j.jphotobiol.2013.09.005.
10. Levina A, Aitken JB, Gwee YY, Lim ZJ, Liu M, Singharay AM, et al. Biotransformation of anticancer ruthenium(III) complexes: An X-ray absorption spectroscopic study. Chem Eur J. 2013;19(11):3609-19. http://dx.doi.org/10.1002/chem.201203127.
11. Kratz F, Messori L. Spectral characterization of ruthenium(III) transfferin. J Inorg Biochem. 1993;49(2):79-82. http://dx.doi.org/10.1016/0162-0134(93)85017-3.
12. Pongratz M, Schluga P, Jakupec MA, Arion VB, Hartinger CG, Allmaier G, et al. Transfferin binding and transfferin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy. J Anal At Spectrom. 2004;19(1):46-51. http://dx.doi.org/10.1039/b309160k.
13. Bratsos I, Jedner S, Gianferrara T, Alessio E. Ruthenium anticancer compounds: Challenges and expectations. Chimia. 2007;61(11):692-7. http://dx.doi.org/10.2533/chimia.2007.692.
14. Menezes CS, de Paula Costa LC, de Melo Rodrigues Avila V, Ferreira MJ, Vieira CU, Pavanin LA, et al. Analysis in vivo of antitumor activity, cytotoxicity and interaction between plasmid DNA and the cis-dichloro-tetra-amine-ruthenium(III) chloride. Chem Biol Interact. 2007;167(2):116-24. http://dx.doi.org/10.1016/j.cbi.2007.02.003.
15. Scholl M, Ding S, Lee CW, Grubbs RH. Synthesis and activity of a new generation of Ruthenium-based olefin metathesis catalysts coordinated with 1, 3-Dimesityl-4, 5-dihydroimidazol-2-ylidene Ligands §. Organic Lett. 1999;1(6):953-6.
http://dx.doi.org/10.1021/ol990909q.
16. Alessio E, Mestroni G, Bergamo A, Sava G. Ruthenium antimetastatic agents. Curren Topics Med Chem. 2004;4(15):1525-35. http://dx.doi.org/10.2174/1568026043387421.
17. Hartinger CG, Jakupec MA, Zorbas‐Seifried S, Groessl M, Egger A, Berger W, et al. KP1019, a new redox‐active anticancer agent–Preclinical development and results of a clinical phase I study in tumor patients. Chem Bio Div. 2008;5(10):2140-55.
http://dx.doi.org/10.1002/cbdv.200890195.
18. da Silva CM, da Silva DL, Modolo LV, Alves RB, de Resende MA, Martins CV, et al. Schiff bases: A short review of their antimicrobial activities. J Adv Res. 2011;2(1):1-8.
http://dx.doi.org/10.1016/j.jare.2010.05.004.
19. Kumar S, Dhar DN, Saxena PN. Applications of metal complexes of Schiff bases-A review. J Sci Ind Res. 2009;68(3):181-7.
20. Nafisi S, Saboury AA, Keramat N, Neault JF, Tajmir-Riahi HA. Stability and structural features of DNA intercalation with ethidium bromide, acridine orange and methylene blue. J Mol Str. 1997;827(1-3):35-43. http://dx.doi.org/10.1016/j.molstruc.2006.05.004.
21. Karacan P, Okay O. Ethidium bromide binding to DNA cryogels. Reac Funct Poly. 2013;73(3):442-50. http://dx.doi.org/10.1016/j.reactfunctpolym.2012.11.014.
22. Vergani L, Mascetti G, Gavazzo P, Nikolini C. Ethidium Bromide intercalation and chromatine structure: A thermal analysis. Thermochimica Acta. 1997;294(2):193-204.
http://dx.doi.org/10.1016/S0040-6031(96)03123-1.
23. Alonso A, Almendral MJ, Curto Y, Criado JJ, Rodriguez E, Manzano JL. Determination of the DNA-binding characteristics of ethidium bromide, proflavine, and cisplatin by flow injection analysis: Usefulness in studies of antitumor drugs. Anal Biochem. 2006;355(2):157-64.
http://dx.doi.org/10.1016/j.ab.2006.06.004.
24. Fiskesjo G. The Allium test as a standard in environmental monitoring. Herreditas. 1985;102(1):99-112. http://dx.doi.org/10.1111/j.1601-5223.1985.tb00471.x.
25. Yildiz M, Cigerci IH, Konuk M, Fidan AF, Terzi H. Determination of genotoxic effects of copper sulphate and cobalt chloride in Allium cepa root cells by chromosome aberration and comet assays. Chemosphere. 2009;75(7):934-8.
http://dx.doi.org/10.1016/j.chemosphere.2009.01.023.
26. Saxena PN, Chauhan LKS, Gupta SK. Cytogenetic effects of commercial formulation of cypermethrin in root meristem cells of Allium sativum: Spectroscopic basis of chromosome damage. Toxicology. 2005;216(2-3):244-52. http://dx.doi.org/10.1016/j.tox.2005.08.008.
27. Saxena PN, Gupta SK, Murthy RC. Carbofuran induced cytogenetic effects in root meristem cells of Allium cepa and Allium sativum: A spectroscopic approach for chromosome damage. Pestic Biochem Phys. 2010;96(2):93-100. http://dx.doi.org/10.1016/j.pestbp.2009.09.006.
28. Herrero O, Perez Martin JM, Fernandez Freire P, Carvajal Lopez L, Peropadre A, Hazen MJ. Toxicological evaluation of three contaminants of emerging concern by use of the Allium cepa test. Mutat Res. 2012;743(1-2):20-4. http://dx.doi.org/10.1016/j.mrgentox.2011.12.028.
29. Ljubijankić N, Zahirović A, Turkušić E, Kahrović E. DNA binding properties of two Ruthenium(III) complexes containing Schiff bases derived from salicylaldehyde: Spectroscopic and electrochemical evidence of CT DNA intercalation. Croat Chem Acta. 2013;86(2):215-22.
http://dx.doi.org/10.5562/cca2216.
30. Kahrović E, Zahirović A, Turkušić E. Calf thymus DNA intercalation by anionic Ru(III) complexes containing tridentate Schiff bases derived from 5-X-Substituted salicyladehyde and 2- Aminophenol. J Chem Chem Eng. 2014;8(4):335-43.
31. Fiskesjo G. Allium test 1: A 2-3 day plant test for toxicity assessment by measuring the mean root growth of onions (Allium cepa L.). Environ Toxicol Water Qual. 1993;8(4):461-70.
http://dx.doi.org/10.1002/tox.2530080410.
32. Kahrovic E. Chemical feature of inorganic compounds as anticancer agents. Health Med. 2011;5(5):1112-6.
33. Kahrović E, Bektaš S, Turkušić E, Zahirović A. Evidence on antimicrobial activity of Sodium dichloro-bis[N-phenyl-5-chlorosalicylideneiminato-N,O]ruthenate(III) against gram positive bacteria. SYLWAN. 2014;158(5):482-93.
34. Kahrović E, Kraljević, Pavelić S. Antiproliferative effect and selectivity of Sodium dichloro-bis [Nphenyl-5-chloro-salicylideneiminato-N,O]ruthenate(III) in vitro. Int J Pharm Pharm Sci. 2015;7(1):86-8.
35. Renjana PK, Anjana S, Thoppil JE. Evaluation of genotoxic effects of baking powder and monosodium glutamate using Allium cepa assay. Int J Pharm Pharm Sci. 2013;5(2):311-5.
36. Mercykutty VC, Stephen J. Adriamycin induced genetic toxicity as demonstrated by Allium test. Cytologia. 1980;45(4):769-77. http://dx.doi.org/10.1508/cytologia.45.769.
37. Patil BC, Bhat GI. A comparative study on MH and EMS in the induction of chromosome aberration on root meristem of Clitoria ternate L. Cytologia. 1992;57(2):259-64.
http://dx.doi.org/10.1508/cytologia.57.259.
38. Nefic H, Handzic I. The effect of age, sex, and lifestyle factors on micronucleus frequency in peripheral blood lymphocytes of the Bosnian population. Mutat Res. 2013;753(1):1-11.
http://dx.doi.org/10.1016/j.mrgentox.2013.03.001.
39. Young SW, Young PW. Effect of plant growth regulators on mitotic chromosomes. The Nucleus. 1993;36:109-13.
40. Turkoglu S. Genotoxicity of five food preservatives tested on root tips of Allium cepa L. Mutat Res. 2007;626(1-2):4-14. http://dx.doi.org/10.1016/j.mrgentox.2006.07.006.
41. Rank J. The method of Allium anaphase-telophase chromosome aberration assay. Ekologija (Vilnius). 2003;1:38-42.
42. Galimberti F, Thompson SL, Ravi S, Compton DA, Dimitrovsky E. Anaphase catastrophe is a target for cancer therapy. Clin Cancer Res. 2011;17(6):1218-22.
http://dx.doi.org/10.1158/1078-0432.CCR-10-1178.
43. Kalcheva VP, Dragoeva AP, Kalchev KN, Enchev DD. Cytotoxic and genotoxic effects of Br-containing oxaphosphole on Allium cepa L. root tip cells and mouse bone marrow cells. Gen. Mol Biol. 2009;32(2):389-93. http://dx.doi.org/10.1590/S1415-47572009000200028.
44. Stepanek O, Brdicka T, Angelisova P, Horvath O, Spicka J, Stockbauer P, et al. Interaction of late apoptotic and necrotic cells with Vitronectin. PLoS One. 2011;6(5):e19243.
http://dx.doi.org/10.1371/journal.pone.0019243.
45. Brabec V, Novakova O. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity. Drug Resist Upd. 2006;9(3):111-22.
http://dx.doi.org/10.1016/j.drup.2006.05.002.
46. Ribeiro Ade S, da Silva CC, Pereira Fde C, Lima AP, Vilanova-Costa CA, Aguiar SS, et al. Mutagenic and genotoxic effects of cis-(dichloro)tetraammineruthenium(III) chloride on human peripheral blood lymphocytes. Biol Trace Elem Res. 2009;130(3):249-61.
http://dx.doi.org/10.1007/s12011-009-8334-9.
47. Hazarika P, Bezbaruah B, Deka J, Deka RP, Medhi OK, Medhi C. The features of protein binding by ruthenium complexes: docking, force field and QM/MM studies. IJRRAS. 2013;14(1):64-74.
48. Kratz F, Hartmann M, Keppler B, Messori L. The binding properties of two antitumor ruthenium(III) complexes to apotransferrin. J Biol Chem. 1994;269(4):2581-8.
Published
2016-10-03
How to Cite
EMINOVIC, Izet et al. Cytogenotoxic effects of two potential anticancer Ruthenium(III) Schiff Bases complexes. Journal of Health Sciences, [S.l.], v. 6, n. 2, p. 112-120, oct. 2016. ISSN 1986-8049. Available at: <http://www.jhsci.ba/OJS/index.php/jhsci/article/view/357>. Date accessed: 18 oct. 2018. doi: https://doi.org/10.17532/jhsci.2016.357.
Section
Research articles

Keywords

ruthenium; Schiff bases; anticancer agents; apoptosis; chromosome aberrations; cytogenotoxic effects
Bookmark and Share